AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Jefferies Group issued their FY2017 earnings estimates for shares of AnaptysBio in a research note issued to investors on Thursday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will post earnings per share of ($1.65) for the year. Jefferies Group currently has a “Buy” rating and a $101.00 price objective on the stock. Jefferies Group also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.40) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($3.27) EPS and FY2021 earnings at ($5.14) EPS.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02.
Several other equities research analysts have also commented on the stock. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a report on Friday. Wedbush restated a “positive” rating and issued a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Stifel Nicolaus restated a “buy” rating and issued a $76.00 price target (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Royal Bank Of Canada boosted their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $81.00.
Shares of AnaptysBio (NASDAQ ANAB) opened at $71.23 on Monday. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $74.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77.
Institutional investors have recently modified their holdings of the company. Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of AnaptysBio by 94.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after buying an additional 9,414 shares during the last quarter. Swiss National Bank purchased a new position in shares of AnaptysBio in the 2nd quarter worth approximately $242,000. State of New Jersey Common Pension Fund D purchased a new position in shares of AnaptysBio in the 3rd quarter worth approximately $1,922,000. Finally, Bank of New York Mellon Corp grew its position in shares of AnaptysBio by 46.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock worth $473,000 after buying an additional 6,297 shares during the last quarter. 59.04% of the stock is currently owned by hedge funds and other institutional investors.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.